Low rates of treatment in postmenopausal women with a history of low trauma fractures: Results of audit in a Fracture Liaison Service

QJM: An International Journal of Medicine

Volumn 103, Issue 1, 2009, Pages 33-40

  Premaor, M O ^a   Pilbrow, L ^b   Tonkin, C ^b   Adams, M ^b   Parker, R A ^c   Compston, J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; RALOXIFENE; STRONTIUM RANELATE; VITAMIN D;

AGED; ANAMNESIS; ARTICLE; FEMALE; FOOT FRACTURE; FRACTURE; HAND FRACTURE; HEALTH SERVICE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; INJURY; LEG FRACTURE; MAJOR CLINICAL STUDY; MEDICAL AUDIT; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; PRIORITY JOURNAL; SPINE FRACTURE; WRIST FRACTURE;

EID: 77950337486     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcp154     Document Type: Article

References (41)

1. Poole KE, Compston JE. Osteoporosis and its management. BMJ 2006; 333:1251-6.
2. Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, et al. A meta-analysis of previous fracture and subsequent fracture risk. Boné 2004; 35:375-82.
3. Klotzbuecher CM, Ross PD, Landsman PB, Abbot TA, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 2000; 15:721-39.
4. National Service Framework for Older People. Department of Health, 2001.
5. Royal College of Physicians. Osteoporosis: Clinical Guidelines for the Prevention and Treatment. London, Royal College of Physicians, 1999.
6. Royal College of Physicians and Bone and Tooth Society of Great Britain. Update on Pharmacological Interventions and an Algorithm for Management. London, UK, Royal College of Physicians, 2000. http://www.rcplondon.ac.uk.
7. Royal College of Physicians. Glucocorticoid-induced osteoporosis. Guidelines on Prevention and Treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. Royal College of Physicians, London, UK, 2002.
8. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate and raloxifene for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Final Appraisal Determination. TAG87. London, NICE, 2005.
9. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Final Appraisal Determination. TAG 161. London, NICE, 2008.
10. National Institute for Health and Clinical Excellence. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. Final Appraisal Determination. TAG 160. London, NICE, 2008.
11. National Clinical Audit of falls and bone health in older people. Clinical Effectiveness and Evaluation Unit. London, Royal College of Physicians, 2007.
12. Hippisley-Cox J, Bayly J, Potter J, Fenty J, Parker C. QResearch. Evaluation of standards of care for osteoporosis and falls in primary care. Final Report to the Information Centre for Health and Social Care, 2007. http://www.qresearch.org/public/publications.aspx.
13. Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 2006; 35:293-305.
14. McLellan AR, Gallacher SJ, Fraser M, McQuillan C. The fracture liaison service: success of a programme for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 2003; 14:1028-34.
15. British Orthopaedic Association. Care of the Patient with Fragility Fracture. September 2007. http://www.boa.ac.uk.
16. World Health Organization Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series, vol. 843, WHO, Geneva, 1994.
17. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, et al. Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 2009; 62:105-8.
18. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, BorgströmF,et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19:399-428.
19. Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, et al. National Osteoporosis Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008; 19:449-58.
20. Siris ES, Miller PD, Barrett-Connor E, Faulkner KG, Wehren LE, Abbott TA, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results from the National Osteoporosis Risk Assessment. JAMA 2001; 286:2815-22.
21. Schuit SCE, van der Klift M, Weel AEAM, de Laet CEDH, Burger H, Seeman E, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 2004; 34:195-202.
22. Wainwright SA, Marshall LM, Ensrud KE, Cauley JA, Black DM. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab 2005; 90:2787-93.
23. Pascoe JA, Seeman E, Henry MJ, Merriman EN, Nicholson GC, Kotowicz MA. The population burden of fractures originates in women with osteopenia, not osteoporosis. Osteoporos Int 2006; 17:1404-9.
24. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomized double blind controlled trial. BMJ 2003; 326:469.
25. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomised Controlled Trial. JAMA 2002; 288:321-33.
26. Kanis JA, Johnell O, Black DM, Downs RW Jr, Sarkar S, Fuerst T, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation Trial. Bone 2003; 33:293-300.
27. Marcus R, Wang O, Satterwhite J, Mitlak B. The skeletal response to teriparatide is largely independent of age, initial bone mineral density and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18:18-23.
28. Watts NB, Josse RG, Hamdy RC, Hughes RA, Manhart MD, Barton I, et al. Risedronate prevents new vertebral fractures in postmenopausal women at high risk. J Clin Endocrinol Metab 2003; 88:542-49.
29. McCloskey EV, Johannsson H, Oden A, Vasireddy S, Kayan K, Pande K, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy-additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 2009; 20:811-7.
30. Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ. The incidence of clinically diagnosed vertebral fractures: a population based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res 1992; 7:221-7.
31. van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone 2001; 29:517-22.
32. Elliot-Gibson V, Bogoch ER, Jamal SA, Beaton DE. Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 2004; 15:767-78.
33. Vanasse A, Dagenais P, Niyonsenga T, Grégoire JP, Courteau J, Hemiari A. Bone mineral density measurement and osteoporosis treatment after a fragility fracture in older adults: regional variation and determinants of use in Quebec. BMC Musculoskelet Disord 2005; 6:33.
34. Jaglal SB, Cameron C, Hawker GA, Carroll J, Jaakkimainen L, Cadarette SM, et al. Development of an integrated-care delivery model for post-fracture care in Ontario, Canada. Osteoporos Int 2006; 17:1337-45.
35. Bessette L, Ste-Marie LG, Jean S, Davison KS, Beaulieu M, Baranci M, et al. The care gap in diagnosis and treatment of women with a fragility fracture. Osteoporos Int 2008; 19:79-86.
36. Haaland DA, Cohen DR, Kennedy CC, Khalidi NA, Adachi JD, Papaioannou A. Closing the osteoporosis care gap-increased osteoporosis awareness among geriatrics and rehabilitation teams. BMC Geriatr 2009; 9:28.
37. Teng GG, Curtis JR, Saag KG. Quality health care gaps in osteoporosis: how can patients, providers and the health system do a better job? Curr Osteoporos Rep 2009; 7:27-34.
38. Murray AW, McQuillan C, Kennon B, Gallacher SJ. Osteoporosis risk assessment and treatment intervention after hip or shoulder fracture. A comparison of two centres in the United Kingdom. Injury 2005; 36:1080-4.
39. Langridge CR, McQuillan C, Watson WS, Walker B, Mitchell L, Gallacher SJ. Refracture following Fracture Liaison Service assessment illustrates the requirement for integrated falls and fracture services. Calcif Tissue Int 2007; 81:85-91.
40. Sander B, Elliot-Gibson V, Beaton BE, Bogoch ER, Maetzel A. A co-ordinator program in post-fracture osteoporosis management improves outcomes and saves costs. J Bone Jt Surg Am 2008; 90:1197-205.
41. TM and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008; 19:385-97.